NERV earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.15. Updated 2026-07-23.
Minerva Neurosciences (NERV) Research Hub
Minerva Neurosciences (NERV) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.15 USD (+0.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.15, market cap 0.03B. This hub links to the full technical, earnings and options research available for NERV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.15 USD (+0.73%) |
| 52-week range | 3.84 USD – 5.84 USD |
| Trend regime | Range |
| 14-day RSI | 48.4 (Neutral) |
| Trailing P/E | -0.15 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for NERV
Covered Call on NERV: how it works, illustrative setup around the real 4.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NERV: how it works, illustrative setup around the real 4.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NERV: how it works, illustrative setup around the real 4.15 USD price, max profit/loss, breakeven and when to use it. Educational.
NERV technical analysis: range, last 4.15 USD, RSI 48.4, 52w range 3.84 USD–5.84 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NERV in?
Minerva Neurosciences (NERV) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NERV in an uptrend or downtrend?
As of 2026-09-11, NERV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NERV's trailing P/E ratio?
NERV's trailing P/E is -0.15, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does NERV next report earnings?
NERV is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.19333 USD.